The Innovative Molecular Analysis Technologies (IMAT) program was established to support the development, technical maturation, and dissemination of novel and potentially transformative next-generation technologies through an approach of balanced but targeted innovation. In support of its mission, the IMAT program utilizes a variety of investigator-initiated research project grant mechanisms while retaining a strong commitment to diversity and to the training of scientists and clinicians in cross-cutting, research-enabling disciplines.
The NCI is very pleased to announce that the IMAT program has approved reissuance for funding opportunity announcements through calendar year (CY) 2013. Please revisit this website for updates on the coming announcements and receipt dates.
Please see the links below for active funding opportunities to understand the FOAs from of the program.
Funding opportunities in technology development are intended to support the inception, maturation, and subsequent dissemination of technically innovative and potentially transformative emerging technologies. These opportunities exist in parallel with various educational and training programs aimed at the recruitment, retention, and promotion of a diverse pool of talent in areas of emerging technology.
The National Cancer Institute is seeking input from the community on identifying priorities with regards to supporting innovative technology development for cancer-relevant research. Please help us by following this link. Ask questions and receive additional insight at our orientation teleconference on May 29 at 3:00 p.m. ET. Dial 1-800-593-0693 and use the passcode “NCI” to join the call. Please note that a full transcript of the teleconference will be made available here if you are not able to attend this call.
IMAT-supported investigator named finalist for Innovation of the Year at the first annual SLAS meeting
Dr. David Beebe has been recognized at the first annual Society for Laboratory Automation & Screening (SLAS) meeting as a finalist for the Innovation of the Year Award for his breakthrough IFAST technology. more +
ThermoScientific to distribute IMAT-supported Iuvo™ technology in their Cellomics high-content analysis platform
The Iuvo™ platform is microchannel cell-based assay which will provide substantial enhancements to the Thermo Fisher Cellomics high-content analysis platform. more +
NCI to host Biospecimen Research Network Symposium: Advancing Cancer Research Through Biospecimen Science
February 22-23, 2012
The symposium highlights new developments in the field of biospecimen science to address the significant impact of pre-analytical biospecimen variables on cancer research and molecular medicine. more +
TransGenomic Corporation Accelerates Acquisition of IMAT Funded Technology
Transgenomic has announced that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI) in Boston. more +
RiboMed Receives $150,000 Epigenetics Research Contract to Continue Work Funded through IMAT to Develop Better Detection Technologies for Cancer more +
Second IMAT investigator named as finalist for ALA Innovation of the Year Award
For the second time in two years, an IMAT investigator has been named as a finalist for the American Laboratory Association's prestigious Innovator of the Year Award. more +
United States Senator featured as Keynote Speaker at IMAT 2009 Principal Investigator's Meeting more +
Two Individual IMAT Investigators Leverage Technologies To Receive Prestigious NIH Director's Transformative R01 Awards more +